



News 1 February 2018

## Follicum launches its new webpage

**Our new webpage, [www.follicum.com](http://www.follicum.com), will make it much easier to access information about our two, main therapy areas, hair growth and diabetes. The starting page will be the English version, as we need to reach an international audience.**

– The website makes it smoother and easier to navigate for all stakeholders, says Jan Alenfall, CEO Follicum. It should be clear what our focus areas are and what's ongoing. Besides much more information about our work on hair growth, we have also added comprehensive information about our work on diabetes and our pre-clinical project with the peptide FOL-014. We will continuously add further information in our work areas as well as about the company in general.

With all activities in hair growth and diabetes, as well as our development of a formulation for FOL-005 we need to create a thorough overview on our activities, both finalised, ongoing and planned. We have attracted attention from outside the Nordic countries and there is a demand for information in English. The website is a part of our vision to become a leading international company, comments Jan Alenfall.

**For more information, please contact:**

Jan Alenfall – CEO, Follicum AB

Phone: +46 46 - 19 21 97

Email: [info@follicum.com](mailto:info@follicum.com)

**About Follicum AB**

*Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. [www.follicum.com](http://www.follicum.com)*

---